Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In patients with hepatocellular carcinoma (HCC), liver transplantation (LT) is an excellent therapy if tumor characteristics are within the Milan criteria. We aimed to define genomic features enabling to identify HCC patients beyond Milan criteria who have acceptable transplant outcomes.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Hepatol.

Title: Journal of hepatology

Publisher: Elsevier BV

ISSN (Electronic): 1600-0641

ISSN (Print): 0168-8278

Publication date (Electronic): Dec 2015

Volume: 63

Issue: 6

Affiliations

[1 ] Mount Sinai Liver Cancer Program (Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Department of Pathology, Recanati Miller Transplantation Institute, Department of Surgical Oncology), Icahn School of Medicine at Mount Sinai, New York, USA.

[2 ] Mount Sinai Liver Cancer Program (Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Department of Pathology, Recanati Miller Transplantation Institute, Department of Surgical Oncology), Icahn School of Medicine at Mount Sinai, New York, USA; Gastrointestinal Surgery and Liver Transplantation Unit, Department of Surgery, National Cancer Institute, Milan, Italy.

[3 ] Mount Sinai Liver Cancer Program (Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Department of Pathology, Recanati Miller Transplantation Institute, Department of Surgical Oncology), Icahn School of Medicine at Mount Sinai, New York, USA; Division of Gastroenterology and Hepatology, University Medicine Cluster, National University Health System, Singapore.

[4 ] Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.

[5 ] Liver Cancer Program, Hofstra-North Shore LIJ School of Medicine, Lenox Hill Hospital, New York, USA.

[6 ] Division of Hepatology, Mayo Clinic, Phoenix, AZ, USA.

[7 ] Gastrointestinal Surgery and Liver Transplantation Unit, Department of Surgery, National Cancer Institute, Milan, Italy.

[8 ] Mount Sinai Liver Cancer Program (Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Department of Pathology, Recanati Miller Transplantation Institute, Department of Surgical Oncology), Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Laboratory, Barcelona - Clínic Liver Cancer Group (Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clínic, Universitat de Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Electronic address: Josep.Llovet@mssm.edu.

Article

Publisher Item ID: S0168-8278(15)00516-4

DOI: 10.1016/j.jhep.2015.07.025

PubMed ID: 26220754

SO-VID: b44b9a06-4562-460b-af44-4561d88f86f9

History

Keywords: Gene expression,Gene signature,Prognosis,Stem cell,Survival

Data availability:

Keywords: Gene expression, Gene signature, Prognosis, Stem cell, Survival

Comments

Comment on this article

scite_

Cited by 30

See all cited by

- Version 1